Mechanisms and predictors of high-risk human papillomavirus (HPV) clearance in the uterine cervix

Cervical cancer (CC) and its precursor lesions (CIN) are unique in that we can study the natural history of one disease at two different levels; i) by assessing the clinical lesions, and ii) by analysing the viral events of human papillomavirus (HPV) infections, their prime etiological agent. In this review, we are interested in mechanisms and predictors of clearance of oncogenic HPV infections in the uterine cervix. The outcome (natural history) of CIN has been well established by a large number of prospective cohort studies covering over 25,000 patients, and the figures for regression, persistence and progression are well established. The outcome of HPV infections is far more complex with at least six distinct patterns being demonstrated in long-term cohort studies. There is little doubt that the mechanistic explanation for HPV clearance is by specific immunological reactions, where competent humoral and cell-mediated immune mediators are needed. To understand this process in detail still necessitates a substantial amount of clinical and laboratory research, however. In general, HPV outcomes follow the pattern where a dynamic balance exists between incident infections and virus clearance. Following a rapid accumulation of incident infections after onset of sexual activity (women < 20 years of age), there is a transition of this balance in favour of virus clearance soon after age 25. This explains the constantly declining age-specific prevalence of HPV infections until menopause. Failure to eradicate the virus at postmenopause is not uncommon, however, explaining the deep second peak in HPV prevalence now reported in many different populations. The importance of HPV clearance/non clearance (= persistence) has been recognised recently, and the number of studies addressing these issues has increased substantially during the past few years. The data are now rather unanimous concerning the times and rates (usually expressed per 1,000 women/months at risk, WMR) of HPV clearance. On the other hand, data are still incomplete and in part inconsistent as to the cofactors that regulate these events. A wide variety of variables have been explored as potential co-determinants and/or predictors of HPV clearance, as reviewed in this communication. Until now, all efforts attempting to identify suitable biomarkers as such predictors, have been disappointing, but fortunately, this is a largely unexplored area as yet. Similarly, data on the two extremes of life, i.e., early infancy and postmenopause, are still far too fragmentary to enable creating a comprehensive view, how these viral infections behave in early life, and what makes many women incapable of clearing their virus at postmenopause. Both issues are of utmost importance and have widespread clinical implications; we need to know how and why some infants and children contract HR-HPV infections well before the onset of their sexual activity, to be able to select the proper targets for prophylactic HPV vaccination. Similarly, we need to know why some women over 55 years of age are likely to remain HR-HPV carriers, while the vast majority successfully clears their infection well before the menopausal age. Early detection of cervical cancer precursors among these elderly HR-HPV positive women past the usual age of organised screening remains a major challenge also in the future.

Human papillomavirus (HPV); Clearance; Outcome; CIN; Cervical cancer; Natural history; Predictors; Biomarkers

[1] Ostor A.G.: "Natural history of cervical intraepithelial neoplasia－a critical review". Int. J. Gynecol. Pathol., 1993, 12, 186.

[2] Syrjiinen K.: "Natural history of cervical HPY infections and CIN". ln: Syrjiinen K. and Syrjanen S. (eds.). Papillomavirus Infections in Human Pathology. New York, J. Wiley & Sons, 2000, 142.

[3] IARC Monographs on the evaluation of carcinogenic risks to humans. Volume 64. Papillomavirusus. Lyon. IARC, 1995, 1.

[4] Syrjiinen K., Syrjanen S.: "Papillomavirus Infections in Human Pathology". New York. J. Wiley & Sons, 2000, 1.

[5] zur Hausen H.: "Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer". J. Natl Cancer Inst., 2001, 93, 252.

[6] Bosch F.X.. Munoz N.: "The viral etiology of cervical cancer". Virus Res., 2002, 89, 183.

[7] Syrjanen K.J.: "Natural history of HPV infections: Recent developments". In: Monsonego J. (ed.). 5th International Multidisciplinary Congress EUROGIN 2003. Milan, Monduzi Editore, 2003, 1.

[8] Ferenczy A., Franco E.: "Persistent human pap仆lomavirus infection and cervical neoplasia". Lancet Oncol., 2003, 3, 11.

[9] Cuzick J., Sasieni P.: "Natural history of cervical human papillomavirus". Lancet: 2001, 358, 1550.

[10] Duggan M.A.: "A review of the natural history of cervical intraepithelial neoplasia". Gan To Kagaku Ryoho, 2002, 29 (suppl. 1), 176.

[11] Paraskevaidis E., Kaponis A., Malamou-Mitsi V., D avidson E.J., Hirsch P.M., Koliopoulos G.:'The natural history of HPV infection of the uterine cervix. Long-term observational and histologicaJ data". Anticancer Res., 2002, 22, 1177.

[12] Franco E.L., Villa L.L., Sobrinho J.P., Prado J.M., Rousseau M.C., Desy M.: "Epidemiology of acquisition and clearance of cervical human Papillomavirus infection in women from a high-risk area for cervical cancer". J. Infect. Dis., 1999, 180, 1415.

[13] J Giuliano A.R., Harris R., Sedjo R.L., Baldwin S.. Roe D., Papenfuss M.R. et al.: "Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study". J. Infect Dis., 2002, 186, 462.

[14] Sellors J.W., Karwalajtys T.L., Kaczorowski J., Mahony J.B., Lytwyn A., Chong S. et al.: "Incidence, clearance and predictors of human papillomavirus infection in women". CMAJ, 2003, 168, 421.

[15] Syrjanen S., Shabalova LP., Petrovichev N., Kozachenko Y.P., ZakharovaT., Pajanidi A. et al.: "Acquisition of incident High-Risk Human Papillomavirus (HPV) DNA and PAP Smear Abnormalities in a Cohort of Women Subjected to HPV Screening in the New Independent States (NIS) of the Former Soviet Union". J. Clin. Microbiol., 2004, 42, 505.

[16] Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Yoorhorst F.J., Bezemer P.O. et al.: "Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear". Lancet, 2001, 358, 1782.

[17] Schiffman M., Wheeler C.M., Castle P.E.:"Human papillomavirus DNA remains detectable longer than related cervical cytologic abnormahties". J. Inject. Dis., 2002, 186, 1169.

[18] Nobbenhuis M.A., Helmerhorst T.J., van den Brule A.J., Rozendaal L., Bezemer P.O., Voorhorst F.J. et al.: "High-risk human papillomav, rusclearance in pregnant women: trends for lower clearance during pregnancy with a catch-up postpartum". Br. J. Cancer, 2002, 87, 75.

[19] Giuliano A.R., Sedjo R.L., Roe DJ., Harri R., Baldwi S., Papenfuss M.R.: "Clearance of oncogenic human papillomavirus (HPY) infection effect of smoking (United States)". Cancer Causes Control, 2002, 13, 839.

[20] Zielinski D.G., Snijders P.J., Rozendaal L., Yoorhorst F.J., Runsink A.P., de Schipper F.A., Meijer CJ.: "High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance". J. Pathol., 2001, 195, 300.

[21] Syrjanen S., Shabalova LP., Petrovichev N., Kozachenko Y.P., Zakharova T., Pajanidi A. et al.: "Clearance of high-risk human papillomavirus (HPY) DNA and PAP smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States (NTS) of the former Soviet Union". Eur. J. Gynecol. Ohstet. Reprod. Biol., 2005, 119, 219.

[22] Syrjiinen S., Shabalova J.P., Petrovichev N., Kozachenko VP., Zakharova T., Pajanidi A. et al.: "Human Papillomavirus testing and conventional PAP smear cytology as optional screening tools of women at different risk for cervical cancer in countries of former SovietUnion". J. Lower Genital Tract Dis., 2002, 6, 97.

[23] Syrjanen S., Shabalova LP.. Petrovichev N., Kozachenko V.P., Zakharova T., Pajandi A. et al.: "Sexual habits and Human papillomavirus (HPV) infections among women in three new independent states of the former Soviet Union". Sex Transm. Dis., 2003, 30, 680.

[24] Syrjanen S., Shabalova LP.. Petrovichev N., Kozachenko VP., Zakharova T., Pajanidi A. et al.: "Age-specific incidence and clearance of highrisk human papillomavirus infections in women in the former Soviet Union". Int. J. STD AIDS, 2005, 16, 217.

[25] Belli L., Frazer I., Hogan P., Kennedy L., O'Connor D., Hersey P. et al.:'·Recurrent condylomata acuminata treated with recombinant interferon alfa-2a: A multicenter double-blind placebo-controlled clinical trial". JAMA, 1991, 265, 2684.

[26] Yliskoski M., Syrjanen K., Syrjanen S., Saarikoski S., Nethersell A.: "Systemic alpha-interferon (Wellferon®) treatment of genital Human papillomavirus (HPV) type 6,11,16 and 18 infections. Double-blind. placebo-controlled trial". Gynecol. Oncol., 1991. 43, 55.

[27] Costa S.. Simone P.O., Venturoli S., Cricca M., Zerbini M.L., Musiani M. et al.: "Factors predicting human papillomavirus clearance In cervical intraepithelial neoplasia lesions treated by conization''. Gynecol. Oncol., 2003, 90, 358.

[28] Konya J., Dillner J.: "Immunity to oncogenic human papillomaviruses". Adv. Cancer Res., 2001, 82, 205.

[29] Campo S. (ed). Papillomavirus Research: From Natural History to Vaccines and Beyond. Norwich, UK. Caister Academic Press, 2006, 1.

[30] Syrjanen K.: "Immunology of HPV infections and prospects for vaccination". Chapter 21. In: Syrjanen K., Syrjlinen S. Papillomavirus Infections in Human Pathology. J., New York, Wiley & Sons, 2000, 459.

[31] Syrjanen K.J.: "Immunocompetent cells in uterine cervical lesions of Human papillomavirus (HPV) origin". Gynecol. Obstet. Invest., 1983, 16, 327.

[32] Syrjanen K., Vayrynen M., Castren O., Mantyjarvi R.. Yliskoski M.:'The relation between the type of immunoreactive cells found in Human papillomavirus (HPV) lesions of the uterine cervix and the subsequent behaviour of these lesions". Arch. Gynecol., 1984, 234, 189.

[33] Viiyrynen M., Syrjiinen K., Miintyjiirvi R., Castren O.. Saarikoski S. Langerhans cells in Human papillomavirus (HPV) lesions of the uterine cervix identified by the monoclonal antibody OKT-6". Int. J. Gynaecol. Obstet., 1984, 22, 375.

[34] Vayrynen M., Syrjanen K., Mantyjarvi R., Castren O., Saarikoski S.: "Immunophenotypes of lymphocytes in prospectiely followed up human papillomavirus lesions of the cervix". Genitourin Med., 1985, 61, 190.

[35] Syrjanen K., Vayrynen M.. Hippelainen M., Castren O., Saarikoski S.. Mantyjarvi R.: "The in situ immunological reactivity and its significance in the clinical behaviour of the cervical Human papillomavirus lesions". Neoplasma, 1985, 32, 181.

[36] Syrjanen K., Vayrynen M., Mantyjarvi R., Castren 0., Saarikoski S.:''Natural killer (NK) cells with HNK-1 phenotype in the cervical biopsies of women followed-up for Human papillomavirus (HPV) lesions". Acta Obstet. Gynecol. Scand., 1986, 65, 139.

[37] Evans E.M., Man S., Evans A.S., Borysiewicz L.K.: "Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes". Cancer Res., 1997, 57, 2943.

[38] Monnier-Benoit S.. Mauny F, Riethmuller D., Guerrini J.S.. Capilna M., Felix S. et al.: "Immunohistochemical analysis of CD4+ and CDS+ T-cell subsets in high risk human pap仆lomavirus-associated pre-malignant and malignant lesions of the uterine cervix". Gynecol. Oncol., 2006, 102, 22.

[39] Steele J.C., Mann C.H., Rookes S., Rollason T., Murphy D., Freeth M.G. et al.:'T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia". Br. J. Cancer, 2005, 93, 248.

[40] Farzaneh F.. Roberts S., Mandal D., Oilier B., Winters U., Kitchener H.C. et al.:'The IL-10 -1082G polymorphism is associated with clearance of HPV infection". BJOG, 2006, I 13, 961.

[41] Doorbar J.: "Molecular biology of human papillomavirus infection and cervical cancer". Clin Sci (Lond), 2006. I IO, 525.

[42] Moscicki A.B., Schiffman M., Kjaer S., Villa L.L.: ·'Updating the natural history of HPV and anogenital cancer". Chapter 5. Vaccine, 2006, 24 (suppl. 3), S42.

[43] Ashrafi G.H., Haghshenas M.R.. Marchetti B., O'Brien P.M., Campo M.S.: "ES protein of human papillomavirus type 16 selectively downregulates surface HLA class I". Int. J. Cance,; 2005, I 13, 276.

[44] Baseman J.G., Koutsky L.A.: "The epidemiology of human papillomavirus infections". J. Clin. Virol., 2005, 32 (suppl. 1), 16.

[45] Maciag P.C., Schlecht N.F., Souza P.S., Rohan T.E., Franco E.L.. Villa L.L.: "Polymorphisms of the human leukocyte antigen DRE 1 and DQB 1 genes and the natural history of human papillomavirus infection". J. Infect. Dis., 2002. 186, 164.

[46] Riethmuller D., Schaal J.P., Mougin C.: "Epidemiology and natural history of genital infection by human papillomavirus". Gynecol. Obstet Fertil., 2002, 30, 139.

[47] Richardson H., Kelsall G., Tellier P., Voyer H., Abrahamowicz M., Ferenczy A. et al.: "The natural history of type-specific human papillomavirus infections in female university students". Cancer Epidemiol. Biomarkers Prev., 2003, 12, 485.

[48] Winer R.L., Kiviat N.B.. Hughes J.P., Adam D.E., Lee S.K.. Kuypers J.M. et al.: "Development and duration of human papillomavirus les10ns, after initial infection". J. Infect. Dis., 2005, 191, 731.

[49] Yeoh G.P., T se M.P.. Chan K.W., Lord L.: "Human papillomavirus DNA and liquid-based cervical cytology cotesting in screening and followup patient groups". Acta Cytol., 2006, 50, 627.

[50] Castle P.E., Schiffman M., Herrero R., Hildesheim A., Rodriguez A.C., Bratti M.C. et al.: "A prospective study of age trends in cervical human Papillomavirus acquisition and persistence in Guanacaste, Costa Rica". J. Infect. Dis., 2005, 191, 1808.

[51] Syrjanen K.. Kulmala S.M., Shabalova LP., Petrovichev N., Kozachenko V.P., Zakharova T. et al.: "Epidemiological, clinical and viral determ1-nants of the increased prevalence of High-Risk Human Papillomavirus (HPV) infections in elderly women". Sex Transm. Dis., 2007; submitted.

[52] Molano M., Van den B.A., Plummer M., Weiderpass E., Posso H.. Arslan A. et al.: "Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study". Am. J. Epidemiol., 2003, 158, 486.

[53] Kulmala S.M., Shabalova I., Petrovitchev N., Syrjanen K., Gyllenstein U., Johansson B., Syrjanen S.:''Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study". Cancer Epidemiol. Biomarker. Prev., 2007, 16, 17.

[54] Syrjanen S., Shabalova LP., Petrovichev N., Kozachenko V.P.. Zakharova T.. Pajanidi A. et al.: "Oral contraceptives are not an independent risk factor for cervical intraepithelial neoplasia or high-risk human papillomavirus infections". Anticancer Res., 2006, 26. 4729.

[55] Hogewoning C.J., Bleeker M.C., van den Brule A.J., Voorhorst F.J., Snijders P.J., Berkhof J. et al.: "Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial". Int. J. Cancer, 2003, 107, 811.

[56] Tokudome S., Suzuki S., Ichikawa H., Hosono A., Maeda K., Marumoto M. et al.: "Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial". Int. J. Cancer, 2004, 112, 164.

[57] Shew M.L., FortenbeITy J.D.. Tu W., Juliar B.E., Batteiger B.E., Qadadri B. et al.: "Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women''. Arch. Pediatr. Adolesc. Med., 2006, 160, 151.

[58] Ahdieh L. Munoz A., Vlahov D., Trimble C.L., Timpson L.A., Shah K.: " Cervical neoplasia and repeated positivity of human papillomav1rus infection in human immunodeficiency virus-seropositive and -seronegative women". Am. J. Epidemiol., 2000, 151, 148.

[59] Branca M., Garbuglia A.R., Benedetto A., Cappiello T., Leoncini L., Migliore G. et al.: "Factors predicting the persistence of genital human papillomavirus infections and PAP smear abnormality in HIV-positive and HIV-negative women during prospective follow-up". Int. J. STD AIDS, 2003, 14, 417.

[60] Koshiol J.E., Schroeder J.C., Jamieson D.J., Marshall S.W., Duerr A., Heilig C.M. et al.: "Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus". Int. J. Cancer, 2006, JI9, 1623.

[61] Syrjanen S., Shabalova J.P., Petrovichev N., Kozachenko VP., Zakharova T., Pajanidi A. et al.: "Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the former Soviet Union". Eur. J. Gynaecol. Oncol., 2005, 26, 491.

[62] Koshiol J., Schroeder J., Jamieson D.J., Marshall S.W., Duerr A., Heilig C.M. et al.: "Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women". Am. J. Epidemiol., 2006, 164, 176.

[63] Richardson H., Abrahamowicz M., Tellier P.P., Kelsall G., du Berger R., Ferenczy A. et al.: "Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students". Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1149.

[64] Piyathilake C.J., Henao O.L., Macaluso M., Cornwell P.E., Meleth S., Heimburger D.C. et al.: "Folate is associated with the natural history of high-risk human papillomaviruses". Cancer Res., 2004, 64, 8788.

[65] Sedjo R.L., Papenfuss M.R., Crati N.E., Giuliano A.R.: "Effect of plasma micronutrients on clearance of oncogenic human papillomavHus (HPV) infection (United States)". Cancer Causes Control, 2003, 14, 319.

[66] Dalstein V., Riethmuller D., Pretet J.L., Le Bail C.K., Sautiere J.L., Carbillet J.P. et al.: "Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study". Int. J. Cancer, 2003, 106, 396.

[67] van Duin M., Snijders P.J., Schrijnemakers H.F., Voorhorst F.J., Rozendaal L., Nobbenhuis M.A. et al.: "Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance". Int. J . Cancer, 2002, 98, 590.

[68] Monnier-Benoit S., Dalstein Y., Riethmuller D., Lalaoui N., Mougin C., Pretet J.L.: "Dynamics of HPVl6 DNA load reflect the natural history of cervical HPV-associated lesions". J. Clin. Virol., 2006, 35, 270.

[69] Wensveen C.W.,K agie M.J.,N agelkerke N.J.,Ve ldhuizen R.W.,T rimbos J.B.: "Can viral load,s emi-quantitatively evaluated,o f human pappillomavirus predict cytological or histological outcome in women with atypical squamous or glandular cells of undetermined significance cytology?". Eur. J. Gynaecol. Oncol., 2005, 26, 393.

[70] Cuschieri K.S., Cubie H.A., W hitley M.W., Gilkison G., Arends M.J., Graham C. et al.: "Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study". J. Clin. Pathol., 2005, 58, 946.

[71] Meijer C., Snijders P.J., Castle P.E.: "Clinical utility of HPV genotyping". Gynecol. Oncol., 2006, 103, 12.

[72] Schlecht N.F., Burk R.D., Palefsky J.M., Minkoff H., Xue X., Massad L.S. et al.: "Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women". J. Gen. Viral., 2005, 86, 2709.

[73] Kadish A.S., Ho G.Y., Burk R.D., Wang Y., Romney S.L., Ledwidge R. et al.: "Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia". J. Natl Cancer Inst., I 997, 89, 1285.

[74] Lorenzato M., Bory J.P., Cucherousset J., Nou J.M., Bouttens D., Thil C. et al.: "Usefulness of DNA ploidy measurementon liquid-based smears showing conflicting results between cytology and high-risk human papillomavirus typing". Am. J. Clin. Pathol., 2002, 118, 708.

[75] von Knebel-Diiberitz M., Syrjanen K.: "Molecular markers. How to apply in practice". Gynecol. Oncol., 2006, 103, 18.

[76] J Santopietro R., Shabalova J.P., Petrovichev N., Kozachenko V.P., Zakharova T., Pajanidi A. et al.: "Cell cycle regulators p 105, p I 07, Rb2/p 130 E2F4, p21cip1/WAF1, Cyclin-A in predicting CIN, High-Risk Human Papillomavirus infections and their outcome in women screened in three New Independent States of the Former Soviet Union". Cancer Epidemiol. Biomarker Prevent., 2006, 15, 1250.

[77] Kjellberg L., Wadell G., Bergman F., Isaksson M., Angstrom T., Dillner J.: "Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser". Am. J. Obstet. Gynecol., 2000, 183, 1238.

[78] Izumi T., Kyushima N., Genda T., Kobayashi N., Kanai T., Wakita K. et al.: "Margin clearance and HPV infection do not influence the cure rates of early neoplasia of the uterine cervix by laser conization". Eur. J. Gynaecol. Oncol., 2000, 21, 251.

[79] Elfgren K., Jacobs M.,Walboomers J.M., Meijer C.J., Dillner J.: "Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia". Obstet. Gynecol., 2002, 100, 965.

[80] Fen J.,Yo shinouchi M.,N akamura K.,K odama J.,N asu Y.,Y amato K. et al.: "Eradication of HPV post-surgical treatments,i ts correlation with specific types, types of surgery and the physical status". Oneal. Rep., 2004, 12, 375.

[81] Verguts J., Bronselaer B., Donders G., Arbyn M., Van E.J., Drijkoningert M. et al.: "Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation". BJOG, 2006, 113, 1303.

[82] Song S.H., Lee J.K., Oh M.J., Hur J.Y., Na J.Y., Park Y.K. et al.: "Persistent HPV infection after conization in patients with negative margins" Gynecol. Oncol., 2006, 101,418.

[83] Cricca M., Venturoli S., Morselli-Labate A.M., Costa S., Santini D., Ambretti S. et al.: "HPV DNA patterns and disease implications in the follow-up of patients treated for HPV l 6 high-grade carcinoma in situ". J. Med. Viral., 2006, 78, 494.

[84] Syrjanen K.J.: "Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis". Eur. J. Gynaecol. Oneal., 2005, 26, 118.

[85] Branca M., Ciotti M., Santini D., Di Bonito L., Benedetto A., Giorgi C. et al.: "p I 61NK40 expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or outcome". Int. J. Gynecol. Pathol., 2004, 23, 354.

[86] Branca M., Ciotti M., Santini D., Bonito L.D., Benedetto A., Giorgi C. et al.: "Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer" Am. J. Clin. Pathol., 2004, 122, 902.

[87] Branca M., Giorgi C., Santini D., Di Bonito L., Ciotti M., Benedetto A. et al.: "Aberrant expression of vascular endothelial growth factor-C (VEGF-C) is related to grade of cervical intraepithelial neoplasia (CJN) and high-risk Human papillomavirus (HPV), but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer". J. Clin. Pathol., 2006, 59, 40.

[88] Branca M., Giorgi C., Santini D., Di Bonito L., Ciotti M., Costa S. et al.: "Aberrant expression of a novel inhittor of apoptosis (Survivin) is related to grade of cervical intraepithelial neoplasia (CIN), but does not predict virus clearance after cone or prognosis in cervical cancer". Am J. Clin. Pathol., 2005, J 24, 113.

[89] Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S. et al.: "Down-regulation of nucleoside diphosphate (NDP) kinase nm23-HI expression is unrelated to high-risk Human papillomavirus (HPV) but associated with progression of CIN and unfavourable prognosis of cervical cancer". J. Clin. Pathol., 2006, 59, 1044.

[90] Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S. et al.: "Over-expression of topoisomerase II is related to the grade of cervical intraepithelial neoplasia (CIN) and high-risk Human papillomavirus (HPV), but does not predict prognosis in cervical cancer or HPV clearance after cone treatment". Int. J. Gynecol. Pathol., 2006, 25, 383.

[91] Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S. et al.: "Relationship of up-regulation of 67-kD laminin receptor to grade of cervical intraepithelial neoplasia and high-risk HPV types and prognosis in cervical cancer". Acta Cytologica, 2006, 50, 6.

[92] Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S. et al.: "Upregulation of nuclear factor-KB (NF-KB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human pap仆lomavirus or disease outcome in cervical cancer". Diagnostic Cytopathol., 2006, 34, 555.

[93] Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S. et al.: "Upregulation of telomerase (hTERT) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus (HPV), virus persistence or disease outcome in cervical cancer". Diagnostic Cytopathol., 2006, 34, 739.

[94] J Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S. et al.: "Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN". Anticancer Res.. 2006, 26, 1543.

[95] Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S. et al.: "Upregulation of proliferating cell nuclear antigen (PCNA) is closely associate with high-risk human papillomavirus (HPV) and progression of cervical intraepithelial neoplasia (CIN), but does not predict disease outcome in cervical cancer". Eur. J. Gynecol. & Ohstet. Reprod. Biol., 2007, 130, 223.

[96] J Branca M.. Giorgi C., Ciotti M., Santini D.. Di Bonito L., Costa S. et al.: "Down-regulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human pap仆lomavirus (HPV) or disease outcome in cervical cancer". Ew: J. Gynaecol. Oncol., 2006, 27, 215.

[97] Branca M., Giorgi C., Ciotti M., Santini D., Di Bonito L., Costa S. et al.: "Predicting high-risk human apillmavirus (HPV) infection, progression of cervical intraepithelial neoplasia (CTN) and prognosis of cervical cancer with a pane of 13 biomarkers tested in multivariate modelling". Gynecol. Oneal., 2007 (submitted).

[98] Sikorski M., Bobek M.. Zrubek H., Marcinkiewicz J.: ·'Dynamics of selected MHC class I and II molecule expression in the course of HPV positive CIN treatment with the use of human recombinant IFN-gamma". Acta Ohstet. Gynecol. Scand.. 2004, 83, 299.

[99] Syrjanen S.: "HPV infections in children. Invited review". Papillomavirus Report, 2003, 14, 93.

[100] Winer R.L.. Koutsky L.A.: "Human papillomavirus through the ages". J. I11fect. Dis., 2005, 191, 1787.

[101] Franceschi S., Herrero R., Clifford G.M., Snijders P.J., Arslan A., Anh P.T. et al.: "Variations in the age-specific curves of human papillamavirus prevalence in women worldwide". Int. J. Cancer. 2006, 119, 2677.

[102] Rintala M.A., Gren man S.E., farvenkyla M.E., Syrjanen K.J., Syrjiinen S.M.: "High-risk types of human papillomavirus (HPV) DNA in oral and genital mucosa of infants during their first 3 years of life: experience from the Finnish HPV Family Study". Clin. Infect. Dis., 2005, 41, 1728.